Title : Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours.

Pub. Date : 2014 Aug 12

PMID : 25025963






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 BACKGROUND: Olaparib, an oral PARP inhibitor, has shown antitumour activity as monotherapy in patients with germline BRCA1/2 (gBRCA)-mutated breast and ovarian cancer. olaparib collagen type XI alpha 2 chain Homo sapiens